# Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07149363/  
OnCo record `nct07149363` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Alliance Foundation Trials, LLC., now recruiting.

## Summary

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07149363 by Alliance Foundation Trials, LLC., with a registry enrolment figure of 65 participants, started 2026-02-12 and due to reach its primary completion in 2029-02. Interventions recorded: Durvalumab 50 MG/ML. Conditions listed: Small Cell Lung Cancer (SCLC). Primary outcome: Disease free survival (DFS). Lung eligibility wording from the registry: "* Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07149363
- Phase: 2
- Setting: Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
- Sponsor: Alliance Foundation Trials, LLC.
- Enrolled: 65

## Sources

- ClinicalTrials.gov NCT07149363: https://clinicaltrials.gov/study/NCT07149363

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07149363.json